This morning Tandem announced they would conduct their fourth quarter and full year conference call on Monday February 24th. As we have noted we don’t expect the launch of the Control IQ to materially impact results. However now that the Control IQ has passed through the FDA and is now in the hands of patients, we have some thoughts on the impact the system will make going forward.
First and foremost the biggest impact will hit Medtronic and hit them hard. Frankly we aren’t the least bit surprised that patients who used the 670G are converting to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.